<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517566</url>
  </required_header>
  <id_info>
    <org_study_id>CZPL389A2203</org_study_id>
    <nct_id>NCT03517566</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, parallel-group study to assess&#xD;
      safety and efficacy of ZPL389 in subjects with moderate to severe atopic dermatitis with a&#xD;
      total study duration up to 24 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A screening period of up to 4 weeks was followed by a 16-week double blinded treatment&#xD;
      period.&#xD;
&#xD;
      After the end of treatment visit, subjects were offered the possibility of ongoing treatment&#xD;
      in the extension study (CZPL389A2203E1/ NCT03948334), or of entering the 4 week&#xD;
      treatment-free follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">August 6, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of IGA Responders at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Investigator's Global Assessment (IGA) score is used to determine the severity of atopic dermatitis symptoms and clinical response to treatment. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. It is a static scale and does not refer to previous status of the subject.&#xD;
IGA response is defined as achievement of an IGA score of 0 or 1 with a 2-point reduction from baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline IGA as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in EASI Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in EASI Score Over Time</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8, Week 12</time_frame>
    <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of EASI50 Responders Over Time</measure>
    <time_frame>Week 2, Week 4, Week 6, Week 8, Week 12, Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.&#xD;
EASI50 response is defined as achieving ≥ 50% improvement (reduction) in EASI score compared to baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline EASI as covariates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of EASI75 Responders Over Time</measure>
    <time_frame>Week 2, Week 4, Week 6, Week 8, Week 12, Week 16</time_frame>
    <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.&#xD;
EASI75 response is defined as achieving ≥ 75% improvement (reduction) in EASI score compared to baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline EASI as covariates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of IGA Responders Over Time</measure>
    <time_frame>Week 2, Week 4, Week 6, Week 8, Week 12</time_frame>
    <description>Investigator's Global Assessment (IGA) score is used to determine the severity of atopic dermatitis symptoms and clinical response to treatment. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. It is a static scale and does not refer to previous status of the subject.&#xD;
IGA response is defined as achievement of an IGA score of 0 or 1 with a 2-point reduction from baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline IGA as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>Up to week 20</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">293</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZPL389 3 mg oral powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZPL389 10 mg oral powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZPL389 30 mg oral powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZPL389 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZPL389 50 mg oral powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily from baseline until week 16</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389 3mg</intervention_name>
    <description>ZPL389 3 mg oral powder; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389 10mg</intervention_name>
    <description>ZPL389 10 mg oral powder; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389 30mg</intervention_name>
    <description>ZPL389 30 mg oral powder; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL389 50mg</intervention_name>
    <description>ZPL389 50 mg oral powder; once daily from baseline to week 16</description>
    <arm_group_label>ZPL389 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must give a written, signed and dated informed consent&#xD;
&#xD;
          -  Chronic atopic dermatitis present for at least 1 year before Baseline&#xD;
&#xD;
          -  Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.&#xD;
&#xD;
          -  Documented recent history (within 6 months before the screening visit) of inadequate&#xD;
             response to treatment with topical medications or for whom topical treatments are&#xD;
             otherwise medically inadvisable&#xD;
&#xD;
          -  Candidate for systemic treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis&#xD;
             disease activity&#xD;
&#xD;
          -  Use of other investigational drugs within 5 half-lives of enrollment, or within 30&#xD;
             days or until the expected pharmacodynamic effect has returned to baseline, whichever&#xD;
             is longer.&#xD;
&#xD;
          -  History of hypersensitivity to any of the study drug constituents or to drugs of&#xD;
             similar chemical classes.&#xD;
&#xD;
          -  Participation in prior ZPL389 studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Market</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Hyacinthe</city>
        <state>Quebec</state>
        <zip>J2S 66</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Karlovy Vary</city>
        <state>Czech Republic</state>
        <zip>36001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novy Jicin</city>
        <state>Czech Republic</state>
        <zip>74101</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague</city>
        <state>Prague 1</state>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrueck</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogur</city>
        <zip>201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>654 0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>220-6208</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>221-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku ku</city>
        <state>Tokyo</state>
        <zip>162 8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>819 0167</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>819-0373</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto</city>
        <zip>606 8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <zip>158 0097</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowian</state>
        <zip>02 495</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35 055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>192007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>194223</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>194325</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>197136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>196240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavropol</city>
        <zip>355020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <state>SVK</state>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <state>Taiwan ROC</state>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO3 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=723</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <results_first_submitted>April 7, 2021</results_first_submitted>
  <results_first_submitted_qc>June 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>AD</keyword>
  <keyword>eczema</keyword>
  <keyword>atopic eczema</keyword>
  <keyword>itch, pruritus</keyword>
  <keyword>histamine 4 receptor</keyword>
  <keyword>antagonist</keyword>
  <keyword>H4R</keyword>
  <keyword>ZPL389</keyword>
  <keyword>ZPL389A2203</keyword>
  <keyword>dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03517566/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03517566/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 293 subjects randomized at baseline to one of the five treatment arms.&#xD;
Two mis-randomized subjects in the placebo arm were excluded from the baseline analysis population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>ZPL389 3mg</title>
          <description>ZPL389 3 mg oral powder</description>
        </group>
        <group group_id="P3">
          <title>ZPL389 10 mg</title>
          <description>ZPL389 10 mg oral powder</description>
        </group>
        <group group_id="P4">
          <title>ZPL389 30mg</title>
          <description>ZPL389 30 mg oral powder</description>
        </group>
        <group group_id="P5">
          <title>ZPL389 50mg</title>
          <description>ZPL389 50 mg oral powder</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="73"/>
                <participants group_id="P5" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Decision /Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects to whom study treatment was assigned. Two Mis-randomized (mis-randomized in Interactive Response Technology (IRT)) subjects in the placebo group were excluded. Mis-randomized subjects were defined as cases where IRT was contacted by the site either prematurely or inappropriately prior to confirmation of the subject's final randomization eligibility and no study medication was administered to the subject.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>ZPL389 3mg</title>
          <description>ZPL389 3 mg oral powder</description>
        </group>
        <group group_id="B3">
          <title>ZPL389 10 mg</title>
          <description>ZPL389 10 mg oral powder</description>
        </group>
        <group group_id="B4">
          <title>ZPL389 30mg</title>
          <description>ZPL389 30 mg oral powder</description>
        </group>
        <group group_id="B5">
          <title>ZPL389 50mg</title>
          <description>ZPL389 50 mg oral powder</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="73"/>
            <count group_id="B5" value="73"/>
            <count group_id="B6" value="291"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="12.79"/>
                    <measurement group_id="B2" value="38.1" spread="11.86"/>
                    <measurement group_id="B3" value="32.1" spread="9.93"/>
                    <measurement group_id="B4" value="34.9" spread="11.69"/>
                    <measurement group_id="B5" value="35.2" spread="11.91"/>
                    <measurement group_id="B6" value="35.0" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of IGA Responders at Week 16</title>
        <description>Investigator's Global Assessment (IGA) score is used to determine the severity of atopic dermatitis symptoms and clinical response to treatment. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. It is a static scale and does not refer to previous status of the subject.&#xD;
IGA response is defined as achievement of an IGA score of 0 or 1 with a 2-point reduction from baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline IGA as covariates.</description>
        <time_frame>Week 16</time_frame>
        <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of IGA Responders at Week 16</title>
          <description>Investigator's Global Assessment (IGA) score is used to determine the severity of atopic dermatitis symptoms and clinical response to treatment. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. It is a static scale and does not refer to previous status of the subject.&#xD;
IGA response is defined as achievement of an IGA score of 0 or 1 with a 2-point reduction from baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline IGA as covariates.</description>
          <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="-1.6" upper_limit="5.3"/>
                    <measurement group_id="O2" value="3.3" lower_limit="-4.3" upper_limit="10.9"/>
                    <measurement group_id="O3" value="7.2" lower_limit="-2.3" upper_limit="16.8"/>
                    <measurement group_id="O4" value="0.8" lower_limit="-2.0" upper_limit="3.7"/>
                    <measurement group_id="O5" value="6.9" lower_limit="0.6" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in EASI Score at Week 16</title>
        <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in EASI Score at Week 16</title>
          <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.</description>
          <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.0" lower_limit="-66.9" upper_limit="-43.1"/>
                    <measurement group_id="O2" value="-49.4" lower_limit="-67.4" upper_limit="-31.4"/>
                    <measurement group_id="O3" value="-50.7" lower_limit="-67.3" upper_limit="-34.1"/>
                    <measurement group_id="O4" value="-46.2" lower_limit="-58.8" upper_limit="-33.6"/>
                    <measurement group_id="O5" value="-52.7" lower_limit="-65.0" upper_limit="-40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in EASI Score Over Time</title>
        <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6, Week 8, Week 12</time_frame>
        <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in EASI Score Over Time</title>
          <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.</description>
          <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" lower_limit="-26.6" upper_limit="-7.5"/>
                    <measurement group_id="O2" value="-20.1" lower_limit="-34.2" upper_limit="-6.1"/>
                    <measurement group_id="O3" value="-10.3" lower_limit="-23.8" upper_limit="3.1"/>
                    <measurement group_id="O4" value="-14.2" lower_limit="-24.0" upper_limit="-4.3"/>
                    <measurement group_id="O5" value="-16.7" lower_limit="-26.4" upper_limit="-7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.7" lower_limit="-30.6" upper_limit="-8.9"/>
                    <measurement group_id="O2" value="-36.1" lower_limit="-51.4" upper_limit="-20.9"/>
                    <measurement group_id="O3" value="-25.6" lower_limit="-40.6" upper_limit="-10.7"/>
                    <measurement group_id="O4" value="-17.7" lower_limit="-29.0" upper_limit="-6.4"/>
                    <measurement group_id="O5" value="-30.0" lower_limit="-40.6" upper_limit="-19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.8" lower_limit="-53.0" upper_limit="-32.6"/>
                    <measurement group_id="O2" value="-47.6" lower_limit="-62.3" upper_limit="-32.9"/>
                    <measurement group_id="O3" value="-43.2" lower_limit="-57.3" upper_limit="-29.0"/>
                    <measurement group_id="O4" value="-33.2" lower_limit="-44.0" upper_limit="-22.3"/>
                    <measurement group_id="O5" value="-43.5" lower_limit="-54.0" upper_limit="-33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.3" lower_limit="-61.1" upper_limit="-37.4"/>
                    <measurement group_id="O2" value="-50.1" lower_limit="-66.8" upper_limit="-33.4"/>
                    <measurement group_id="O3" value="-47.4" lower_limit="-63.9" upper_limit="-30.9"/>
                    <measurement group_id="O4" value="-38.1" lower_limit="-50.5" upper_limit="-25.7"/>
                    <measurement group_id="O5" value="-45.5" lower_limit="-57.4" upper_limit="-33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.4" lower_limit="-66.0" upper_limit="-44.8"/>
                    <measurement group_id="O2" value="-48.7" lower_limit="-64.2" upper_limit="-33.2"/>
                    <measurement group_id="O3" value="-54.1" lower_limit="-69.2" upper_limit="-39.1"/>
                    <measurement group_id="O4" value="-45.1" lower_limit="-56.4" upper_limit="-33.8"/>
                    <measurement group_id="O5" value="-52.7" lower_limit="-63.7" upper_limit="-41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of EASI50 Responders Over Time</title>
        <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.&#xD;
EASI50 response is defined as achieving ≥ 50% improvement (reduction) in EASI score compared to baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline EASI as covariates</description>
        <time_frame>Week 2, Week 4, Week 6, Week 8, Week 12, Week 16</time_frame>
        <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of EASI50 Responders Over Time</title>
          <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.&#xD;
EASI50 response is defined as achieving ≥ 50% improvement (reduction) in EASI score compared to baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline EASI as covariates</description>
          <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="1.1" upper_limit="12.9"/>
                    <measurement group_id="O2" value="15.0" lower_limit="3.1" upper_limit="27.0"/>
                    <measurement group_id="O3" value="12.6" lower_limit="1.1" upper_limit="24.1"/>
                    <measurement group_id="O4" value="5.8" lower_limit="0.3" upper_limit="11.2"/>
                    <measurement group_id="O5" value="10.1" lower_limit="3.1" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="5.9" upper_limit="21.9"/>
                    <measurement group_id="O2" value="19.0" lower_limit="5.4" upper_limit="32.5"/>
                    <measurement group_id="O3" value="20.1" lower_limit="6.1" upper_limit="34.1"/>
                    <measurement group_id="O4" value="9.5" lower_limit="2.4" upper_limit="16.7"/>
                    <measurement group_id="O5" value="20.7" lower_limit="11.4" upper_limit="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="9.4" upper_limit="27.4"/>
                    <measurement group_id="O2" value="15.0" lower_limit="2.5" upper_limit="27.5"/>
                    <measurement group_id="O3" value="15.1" lower_limit="2.5" upper_limit="27.7"/>
                    <measurement group_id="O4" value="9.5" lower_limit="2.1" upper_limit="16.8"/>
                    <measurement group_id="O5" value="16.7" lower_limit="8.0" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="9.7" upper_limit="28.0"/>
                    <measurement group_id="O2" value="18.0" lower_limit="4.5" upper_limit="31.5"/>
                    <measurement group_id="O3" value="16.4" lower_limit="3.3" upper_limit="29.5"/>
                    <measurement group_id="O4" value="9.4" lower_limit="2.2" upper_limit="16.6"/>
                    <measurement group_id="O5" value="12.8" lower_limit="4.8" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" lower_limit="10.9" upper_limit="29.7"/>
                    <measurement group_id="O2" value="11.4" lower_limit="-0.4" upper_limit="23.1"/>
                    <measurement group_id="O3" value="20.3" lower_limit="5.8" upper_limit="34.9"/>
                    <measurement group_id="O4" value="12.6" lower_limit="4.3" upper_limit="20.9"/>
                    <measurement group_id="O5" value="12.0" lower_limit="4.2" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="7.9" upper_limit="25.8"/>
                    <measurement group_id="O2" value="14.4" lower_limit="1.4" upper_limit="27.3"/>
                    <measurement group_id="O3" value="22.7" lower_limit="7.5" upper_limit="37.9"/>
                    <measurement group_id="O4" value="12.1" lower_limit="3.9" upper_limit="20.3"/>
                    <measurement group_id="O5" value="12.7" lower_limit="4.6" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of EASI75 Responders Over Time</title>
        <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.&#xD;
EASI75 response is defined as achieving ≥ 75% improvement (reduction) in EASI score compared to baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline EASI as covariates</description>
        <time_frame>Week 2, Week 4, Week 6, Week 8, Week 12, Week 16</time_frame>
        <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of EASI75 Responders Over Time</title>
          <description>Eczema Area and Severity Index (EASI) is used to assess the extend and severity of atopic dermatitis on a scale from 0 to 72 where 72 is worst eczema.&#xD;
EASI75 response is defined as achieving ≥ 75% improvement (reduction) in EASI score compared to baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline EASI as covariates</description>
          <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-3.0" upper_limit="4.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-3.1" upper_limit="4.4"/>
                    <measurement group_id="O4" value="1.4" lower_limit="-1.3" upper_limit="4.1"/>
                    <measurement group_id="O5" value="1.5" lower_limit="-1.4" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="-1.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="7.0" lower_limit="-2.0" upper_limit="16.0"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-3.9" upper_limit="7.2"/>
                    <measurement group_id="O4" value="1.8" lower_limit="-1.6" upper_limit="5.2"/>
                    <measurement group_id="O5" value="1.4" lower_limit="-1.3" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="0.3" upper_limit="10.9"/>
                    <measurement group_id="O2" value="10.3" lower_limit="-0.4" upper_limit="21.0"/>
                    <measurement group_id="O3" value="7.1" lower_limit="-1.9" upper_limit="16.1"/>
                    <measurement group_id="O4" value="1.8" lower_limit="-2.0" upper_limit="5.7"/>
                    <measurement group_id="O5" value="7.4" lower_limit="1.2" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0.4" upper_limit="11.6"/>
                    <measurement group_id="O2" value="10.9" lower_limit="-0.2" upper_limit="21.9"/>
                    <measurement group_id="O3" value="8.5" lower_limit="-1.8" upper_limit="18.8"/>
                    <measurement group_id="O4" value="2.5" lower_limit="-1.8" upper_limit="6.8"/>
                    <measurement group_id="O5" value="6.1" lower_limit="0.4" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="-0.4" upper_limit="9.6"/>
                    <measurement group_id="O2" value="6.2" lower_limit="-3.1" upper_limit="15.6"/>
                    <measurement group_id="O3" value="10.6" lower_limit="-0.9" upper_limit="22.0"/>
                    <measurement group_id="O4" value="2.8" lower_limit="-1.6" upper_limit="7.2"/>
                    <measurement group_id="O5" value="5.8" lower_limit="-0.0" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.6" upper_limit="16.8"/>
                    <measurement group_id="O2" value="7.1" lower_limit="-2.8" upper_limit="16.9"/>
                    <measurement group_id="O3" value="12.9" lower_limit="0.3" upper_limit="25.5"/>
                    <measurement group_id="O4" value="3.1" lower_limit="-1.7" upper_limit="7.8"/>
                    <measurement group_id="O5" value="9.3" lower_limit="2.1" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of IGA Responders Over Time</title>
        <description>Investigator's Global Assessment (IGA) score is used to determine the severity of atopic dermatitis symptoms and clinical response to treatment. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. It is a static scale and does not refer to previous status of the subject.&#xD;
IGA response is defined as achievement of an IGA score of 0 or 1 with a 2-point reduction from baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline IGA as covariates.</description>
        <time_frame>Week 2, Week 4, Week 6, Week 8, Week 12</time_frame>
        <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of IGA Responders Over Time</title>
          <description>Investigator's Global Assessment (IGA) score is used to determine the severity of atopic dermatitis symptoms and clinical response to treatment. It reflects a subject's overall disease severity for the whole body. The scale includes 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. It is a static scale and does not refer to previous status of the subject.&#xD;
IGA response is defined as achievement of an IGA score of 0 or 1 with a 2-point reduction from baseline without use of confounding therapy (e.g. rescue medication) up to the assessment time point.&#xD;
Treatment discontinuations for lack of efficacy or adverse event are considered non-responders.&#xD;
Percentage of responders was calculated based on a logistic regression model with response as outcome variable and treatment (dose as categorical variable) and baseline IGA as covariates.</description>
          <population>Full analysis set (FAS) comprised all subjects who were randomized and to whom study treatment had been assigned. Mis-randomized subjects (mis-randomized in IRT) were excluded from the FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="-2.5" upper_limit="7.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.7" upper_limit="0.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="-2.6" upper_limit="8.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1.4" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.6" upper_limit="0.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-0.4" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-1.3" upper_limit="4.1"/>
                    <measurement group_id="O2" value="6.1" lower_limit="-2.1" upper_limit="14.4"/>
                    <measurement group_id="O3" value="5.9" lower_limit="-2.0" upper_limit="13.8"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1.9" upper_limit="2.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-1.2" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="-1.4" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.8" lower_limit="-3.1" upper_limit="10.7"/>
                    <measurement group_id="O3" value="6.5" lower_limit="-2.1" upper_limit="15.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-1.7" upper_limit="2.7"/>
                    <measurement group_id="O5" value="2.0" lower_limit="-1.6" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-1.4" upper_limit="4.4"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-3.3" upper_limit="11.3"/>
                    <measurement group_id="O3" value="5.6" lower_limit="-3.1" upper_limit="14.2"/>
                    <measurement group_id="O4" value="1.9" lower_limit="-1.6" upper_limit="5.5"/>
                    <measurement group_id="O5" value="1.0" lower_limit="-2.1" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.</description>
        <time_frame>Up to week 20</time_frame>
        <population>Safety Set included all subjects who received at least one dose of study medication. Subjects were analyzed according to treatment received. The safety analyses were based on safety sets (SAF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>ZPL389 3mg</title>
            <description>ZPL389 3 mg oral powder</description>
          </group>
          <group group_id="O3">
            <title>ZPL389 10 mg</title>
            <description>ZPL389 10 mg oral powder</description>
          </group>
          <group group_id="O4">
            <title>ZPL389 30mg</title>
            <description>ZPL389 30 mg oral powder</description>
          </group>
          <group group_id="O5">
            <title>ZPL389 50mg</title>
            <description>ZPL389 50 mg oral powder</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.</description>
          <population>Safety Set included all subjects who received at least one dose of study medication. Subjects were analyzed according to treatment received. The safety analyses were based on safety sets (SAF).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 4 weeks post treatment, up to maximum duration of 20 weeks</time_frame>
      <desc>Any sign or symptom that occurs during the study treatment plus the 4 weeks post treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>ZPL389 3 mg</title>
          <description>ZPL389 3 mg oral powder</description>
        </group>
        <group group_id="E3">
          <title>ZPL389 10 mg</title>
          <description>ZPL389 10 mg oral powder</description>
        </group>
        <group group_id="E4">
          <title>ZPL389 30 mg</title>
          <description>ZPL389 30 mg oral powder</description>
        </group>
        <group group_id="E5">
          <title>ZPL389 50 mg</title>
          <description>ZPL389 50 mg oral powder</description>
        </group>
        <group group_id="E6">
          <title>All Patients</title>
          <description>All Patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Herpes dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Risk of future pregnancy miscarriage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="105" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="291"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="291"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

